Phase 3 Study of Oral Therapy for ‘Off’ Episodes in Parkinson’s Now Enrolling Patients

Cynapsus Therapeutics recently provided an update on APL-130277, its sublingual formulation of apomorphine hydrochloride or apomorphine. Apomorphine injection is the only treatment approved for acute, intermittent “off” episodes in advanced Parkinson’s disease (PD) patients. Motor symptoms such as tremor at rest, rigidity, and impaired movement or freezing, as well as difficulties with starting…

Data from Studies on PKAN and ‘Off’ Episodes in Parkinson’s Presented at 2016 Congress

Retrophin presented new data from a physician-initiated study of RE-024, the company’s investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare movement disorder. The findings, from treatment in two adults with PKAN, suggest the treatment is both safe and effective, with patients showing clinical improvement and stable disease progression. These results, as well as…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums